The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration launched by the National Institutes of Health, the Foundation for the National Institutes of Health, and 12 leading pharmaceutical companies as part of the Cancer Moonshot. PACT works in collaboration with the CIMAC-CIDC Network to facilitate systematic and uniform clinical testing of biomarkers to advance understanding of the mechanisms of response and resistance to cancer therapy.

The research conducted under this partnership is focused on integrating immune and other related oncology biomarkers into clinical trials by defining a set of standardized biomarkers to be tested across a variety of studies. This approach allows for consistent generation of data, uniform and harmonized assays to support data reproducibility, comparability of data across trials, and discovery and validation of new biomarkers for immunotherapy and related combinations.

The PACT public-private partnership is managed by the Foundation for the National Institutes of Health (FNIH) with the Food and Drug Administration serving in an advisory role.

Scientific and financial support for the PACT partnership are made possible through funding support provided to the FNIH by:

AbbVie Inc.
Amgen Inc.
Boehringer-Ingelheim Pharma GmbH & Co. KG
Bristol-Myers Squibb
Celgene Corporation
Genentech Inc.
GlaxoSmithKline plc
Janssen Pharmaceutical Companies of Johnson & Johnson
Novartis Institutes for Biomedical Research
Pfizer Inc.